← 返回

浸润性及原位导管乳腺癌中 TIL(肿瘤浸润淋巴细胞)、三级淋巴结构(TLS)及 TIL 上 PD-1、TIM-3、LAG-3 的表达及其与预后因素的关系

英文原题:Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors.

查看英文原题

Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors.

PubMed 2022/08/20(内容时间) Clin Breast Cancer Q3 · IF 2.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

在乳腺癌中评估 TIL 和免疫控制点受体表达,对于规划基于免疫治疗方案的治疗方法尤为重要。

研究思路结论见上方概要

免疫治疗已被确定为乳腺癌的重要选择,尤其是在炎症反应显著的肿瘤中。在这一前景广阔的领域,TIL(肿瘤浸润淋巴细胞)以及TIL上免疫检查点受体的表达已变得日益重要。

本研究对312例浸润性乳腺癌和68例原位乳腺癌患者的肿瘤组织中基质TIL和三级淋巴结构(TLS)进行了检测。通过免疫组化评估了肿瘤内和基质TIL上PD-1、LAG-3和TIM-3的表达率。

在浸润性乳腺癌中,发现间质TIL与淋巴结转移、HR和HER2表达以及基底样表型显著相关,而TLS的存在与新辅助治疗、复发、死亡以及HR和HER2表达相关。发现PD-1、LAG-3和TIM-3表达与HR和HER2状态、间质TIL率和TLS相关。在多变量分析中,发现高间质TIL和肿瘤内TIL中PD-1表达在总生存期和无病生存期方面是独立预后因素。

展开英文摘要原文

In this study, stromal TIL and tertiary lymphoid structures (TLS) were determined in tumor tissues of 312 invasive and 68 in situ breast cancer patients. Expression rates of PD-1, LAG-3, and TIM-3 on intratumoral and stromal TIL were immunohistochemically evaluated.

In invasive breast carcinomas, stromal TIL was found to be significantly associated with lymph node metastasis, HR and HER2 expression, and basal-like phenotype, as the presence of TLS with neoadjuvant therapy, recurrence, death, and expression of HR and HER2. PD-1, LAG-3, and TIM-3 expressions were found to be associated with HR and HER2 status, stromal TIL rates, and TLS. In multivariate analysis, high stromal TIL and PD-1 expression in intratumoral TIL were found to be independent prognostic factors in terms of overall survival and disease-free survival.

Evaluation of TIL and immune control point receptor expressions in breast cancer is particularly important in terms of planning the therapeutic approaches based on immunotherapy protocols.

论文信息

作者
Acar E、Esendağlı G、Yazıcı O、Dursun A
单位
Department of Medical Pathology, Ömer Halis Demir University, Niğde, Turkey. Electronic address: e.elifacar@hotmail.com.Turkey
文献类型
非美国政府资助研究
期刊
Clinical breast cancer2022 Dec
原文标识
PubMed 36089459 · DOI 10.1016/j.clbc.2022.08.005